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1. Introduction
1.1. E˝idence for a role for PKC in T cell acti˝ation
 .Following the discovery of protein kinase C PKC
in 1977 by Nishizuka’s group, a potential role for the
cyclic nucleotide independent enzyme in the regula-
tion of lymphocyte function was proposed. Identifica-
w xtion of PKC as the cellular phorbol ester receptor 1
further strengthened the role for this enzyme in T cell
function as previous studies had reported that phorbol
w xesters were mitogenic for lymphocytes 2,3 . High
levels of PKC activity were found in human periph-
 . w xeral blood lymphocytes PBL 4 and PKC was
subsequently shown to be activated in response to
various T cell agonists including phytohaemagglu-
 .  .tinin PHA , phorbol 12-myristate 13-acetate PMA
 . w xand interleukin-2 IL-2 5,6 . The advent of mono-
 .clonal antibodies to the T cell receptor TCR –CD3
complex lead to identification of PKC as a down-
stream signalling molecule following cross-linking of
the antigen receptor. Cross-linking of TCR–CD3 was
initially shown to induce increases in free cytoplas-
mic calcium ions and increased generation of inositol
w xtrisphosphate 7 . Further studies illustrated that PKC
translocation and substrate phosphorylation were an
important consequence of T cell activation via the
w xTCR–CD3 complex 8 .
Since the original studies that suggested that PKC
had an important role in T cell signalling, our under-
standing of the function of PKC in T cells has
progressed considerably. PKC activators have been
shown to induce a number of biochemical events in T
cells which result in progression into the mitotic
cycle, expression of the high affinity receptors for
IL-2, secretion of IL-2, cytoskeletal rearrangements,
downmodulation of surface receptors, activation of
the lytic function of cytotoxic T cells and transcrip-
tion of many genes including those for IL-2 and other
w xcytokines and their receptors 9,10 . In this review,
we discuss the multiple diverse functions of PKC in
T cell function both at a ‘housekeeping’ level and in
relation to specific T cell functions. The emerging
information on isoform specific T cell functions is
also addressed.
Protein kinase C is a multigene family of serine–
threonine kinases that is subgrouped into three differ-
ent sections based on similar structural features and
activation requirements. The conventional cPKC’s a ,
b 1, b 2, and g are activated by calcium, phos-
 .  .phatidylserine PS , and diacylglycerol DAG or
phorbol esters. Additional endogenous activators in-
clude cis-unsaturated fatty acids and lysophosphati-
 .dylcholine lysoPC . The expression of these iso-
forms is thought to be universal, although PKC g
expression is more restricted compared to the other
cPKC’s. nPKC « , d , h, m and u are known as the
novel or new PKC isoforms. The distinguishing fea-
ture of novel PKC’s from traditional cPKC’s is they
lack a C domain which allows them to function in a2
calcium independent manner. Individual members of
this class are activated by different combinations of
lipids, i.e. PKC « is activated by cis-unsaturated
fatty acids but PKC d is not. Similarly different
patterns of tissue expression have been observed for
w xnovel PKC’s 11 . Expression of PKC u is limited
primarily to lymphocytes and skeletal muscle and it
is among the most abundant of the PKC isozymes in
w xT lymphocytes 12 . The final group of atypical
PKC’s is composed of two members z and i_l,
PKC i is the human homolog of mouse PKC l. In
contrast to the other PKC isoforms the atypical PKC
isoforms cannot be regulated by calcium, phorbol
esters, or DAG but are regulated by other lipid
 .cofactors such as phosphatidylinositol 3,4,5 trispho-
 . w x w xsphate PIP 13 and ceramide 14 .3
T lymphocytes constitute one of the major classes
of lymphocytes. They are derived from precursors in
the bone marrow which differentiate in the thymus
where they are known as thymocytes. Naive T cells
exit the thymus as CD4q or CD8q cells expressing
either an ab or gd TCR. The CD4 and CD8 pheno-
type corresponds generally but not exclusively with
 .the helper T cell or cytotoxic T cell CTL function,
respectively. CD4q T helper cells regulate the func-
tion and activity of T cells, B cells, CTL’s,
macrophages, other inflammatory leukocytes and the
vascular endothelium through the production of a
range of cytokines such as IL-2, IL-4, IL-15, IL-10,
etc. T helper cells are often referred to as either Th-1
or Th-2 cells based on the pattern of cytokines they
 .produce see Section 2.6 . CTLs are involved in a
number of functions including the elimination of
virally infected cells. They mediate target cell lysis
by two methods a perforin–granzyme based mecha-
nism and an apoptotic mechanism usually following
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 .activation of the TCR see Section 2.7 . Following
removal of an infectious agent the immune system is
left in a state of immunologic memory. Some of the
progeny of antigen-specific T cells develop into anti-
gen-specific memory T cells which are involved in
initiation of larger secondary immune responses upon
subsequent exposure to the antigen. These memory
cells may be recognised by the switch in expression
of the CD45 surface molecule from CD45RA to
CD45RO. T cells are characterised by expression of
the T cell receptor and an associated signalling com-
plex known as CD3. The T cell receptor recognises
 q .antigen complexed to MHC class I CD8 T cells or
 q .MHC class II CD4 T cells , respectively. Activa-
tion of the T cell receptor through this complex
results in a series of signalling events largely trans-
 .duced through CD3 as will be discussed further .
The net effect of such signalling is generally to
activate the intracellular machinery necessary for cell
proliferation, cytokine production, cytolysis and thus
the differentiation of ‘naive’ peripheral T cells into
effector cells. This review addresses the key role that
PKC plays in T cell activation and effector function.
1.2. Signalling pathways upstream and parallel to
PKC in T cells
Prior to addressing the localisation and putative
functions of PKC in T cells we will firstly describe
the steps leading to the activation of PKC in these
cells. Members of the PKC family have the potential
to be activated by a variety of membrane lipid
 .metabolites including DAG, phosphatidic acid PA ,
lysoPC, cis-unsaturated fatty acids and PIP . In this3
section the ‘immediate’ signalling events following
engagement of the T cell receptor–CD3 complex
 .with MHC on the antigen presenting cell APC that
result in the generation of these lipid cofactors are
Fig. 1. PKC signaling pathways and crosstalk in T lymphocytes. An overview of some of the signaling pathways leading to activation of
IL-2 gene transcription with which specific PKC isoforms are thought to interact are illustrated. Some of these pathways are still
hypothetical. For details of evidence for the involvement of specific PKC isoforms in the activation of transcription factors NFAT, AP-1
and NFk B: refer to the text. PTK – protein tyrosine kinase, AA – arachidonic acid, ? indicates unknown function or interaction.
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examined. Additional signalling pathways with which
PKC may cross talk are also briefly discussed. Fig. 1
presents an overview of these interactions.
Cross-linking of T cell receptor and coreceptors
gives rise to sequential activation of two families of
 .protein tyrosine kinases-PTK src and ZAP 70 fol-
lowed by activation of a range of phospholipases
w x15 . The phospholipases convert membrane lipids
into second messengers which release intracellular
calcium and activate PKC. The src family of tyrosine
kinases lck, fyn and yes, are the first kinases to be
activated following TCR-MHC cross-linking. In T
cells lck, the best characterised of this family, is
associated with CD4r8 cytoplasmic tails. Following
T cell activation, rapid lck induced tyrosine phospho-
rylation of the z chain of the CD3 complex can be
w xdetected 16 . z subunit phosphorylation provides a
docking site for the tyrosine kinase ZAP 70. Follow-
ing association of ZAP 70 with the TCR–CD3 com-
plex an increase in tyrosine kinase activity can be
detected. While substrates of ZAP 70 have not yet
w xbeen conclusively identified 17 , an increase in tyro-
sine phosphorylation of PLC g has been observed in
activated lymphocytes and it is thought that this is
mediated either directly or indirectly by ZAP 70 or
lck. Tyrosine phosphorylation of PLC g activates the
enzyme which catalyses the conversion of membrane
phospholipids into IP and DAG which release intra-3
cellular calcium and activate PKC, respectively. In-
creasing evidence suggests that several other phos-
 .pholipases including phospholipase D PLD , phos-
 .  .pholipase A PLA , sphingomyelinase SMase and2 2
the lipid kinase phosphatidyl inositol-3 kinase PI-3
.kinase play an important role in the production of
cofactors for PKC activation following TCR cross-
w xlinking 10 .
PLD activation has been proposed to be important
in the regulation of gene expression during T cell
w xactivation 18 . PA, the physiological product of PLD
activity can be further hydrolysed to produce DAG or
lysoPC. The DAG species derived from PA, in addi-
tion to PA itself, and lysoPC have all been implicated
w xas having a mitogenic role in lymphocytes 10 .
These lipids have also been shown to activate PKC
w xwith some exhibiting isoform specificity 19 . Anti-
genic activation of T cells has also been shown to
result in the production of lysoPC and cis-un-
saturated fatty acids through the activation of PLA 2
w x20 . It has been illustrated that Lyso PC can enhance
the DAG induced activation of human T lymphocytes
as measured by IL-2 receptor expression and prolifer-
w xation 20 . Both Lyso PC and cis-unsaturated fatty
w xacids have been shown to activate PKC 19 and
cis-unsaturated fatty acids have been shown to poten-
tiate cellular responses in DAG stimulated human T
w xlymphocytes 11 .
The novel lipid kinase PI-3 kinase has also been
shown to be activated following T cell receptor stim-
ulation and it is thought that this enzyme may be
w xassociating with the CD28 coreceptor 21 and CD4r8
w x22 . Although the exact mechanism of receptor cou-
pling to PI-3 kinase is unknown in TCR and CD4
activated T cells a novel protein termed Lnk has been
shown to couple the T cell receptor to PI-3 kinase
w xand PLC g 23 . In vitro PKC isoform specificity has
been demonstrated for the metabolites of PI-3 kinase
w x
– PIP and PIP 13 , although the specific PKC2 3
isoforms activated in T cells have not yet been
characterised in vivo. The production of ceramide via
the action of SMase has also been implicated as a
potential signalling process in lymphocytes. TNF a
induced production of ceramide specifically activates
w xPKC z in U937 cells 24 , however, whether this
pathway for activation of PKC z exists in T cells has
yet to be clarified.
Thus several phospholipases have been implicated
in the regulation of PKC during T cell activation. It
has been suggested that activation of these enzymes
w xmay be dependent on the stage of cell activation 19 .
The immediate cell responses following T cell activa-
tion may be mediated by metabolites generated by
activation of PLC g and PI-3 kinase whereas the long
term responses including IL-2 production may be
mediated by the downstream effects of activation of
PLD, PLA and possibly SMase. The process of T2
cell activation may therefore involve the production
of specific lipid second messengers that serve to
activate PKC and other signalling molecules at de-
fined temporal stages following stimulation.
 .p21Ras ras is a low molecular weight GTP
binding protein that has an important role in T cell
activation. Ras has been shown to be involved in the
w xregulation of IL-2 gene transcription 25 . Following
TCR-MHC cross-linking and activation of PTK’s of
the src and ZAP 70 family, the adapter protein Shc
becomes tyrosine phosphorylated and associates with
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Grb2 via its SH2 domain. Grb2 then binds mSOS and
shuttles it to the membrane where it activates ras
w x25,26 . The signalling pathway that links activated
ras to gene transcription has been proposed to in-
w xvolve the raf-1-MAP kinase pathway 27 . It has also
been shown that phosphorylation and activation of
raf-1 via the T cell antigen receptor is a PKC depen-
w xdent process 28 . Thus p21ras and PKC appear to
operate in T cells both upstream and downstream of
each other and in a colinear signalling pathway.
1.3. PKC isoforms in T cells
Several studies have examined the expression of
conventional PKC isoforms in lymphocytes and T
w xcell lines from various species. Brandt et al. 29 were
the first to describe the presence of two PKC mes-
sage transcripts in rat lymphoid tissue. Human T
lymphocytes were subsequently reported to express
PKC a and b at the protein level by Shearman et al.
w x30 . The conventional PKC g isoform has also been
w xdetected in human PBL’s at the mRNA 31 and
w xprotein level 32 although at lower levels compared
to that expressed in brain. A number of studies have
suggested a specific role for PKC b in T cell func-
w xtion. Kelleher and Long 33 reported that IL-2 pro-
duction was defective in K-4 cells which do not
express PKC b. Introduction of anti-PKC b antibod-
ies into T cells by electroporation has been shown to
inhibit IL-2 production and lymphocyte proliferation
w x34 . However, in PKC b knockout mice thymocyte
development appears to be similar to normal mice,
and there is normal expression of the TCR–CD3
w xcomplex 35 . PKC b has also been reported to
colocalise with spectrin and ankyrin in resting and
PMA activated murine lymphocytes, suggesting a
role for this isoform in lymphocyte cytoskeletal rear-
w xrangement 36 . The relative contribution of each of
the conventional PKC isoforms to T cell function
may depend on the stage of development of the
lymphocyte and on the interaction of other PKC
isoforms activated by specific stimuli.
The expression of calcium-independent PKC iso-
forms in T cells was initially examined using murine
w xT cells and human T cell lines. Mischak et al. 37
reported that following screening of a number of
mouse T cell lines PKC h expression was the high-
est, with PKC d and z being expressed at low levels
and PKC « expressed in trace amounts. This study
also examined expression of these isoforms in murine
lymph node T cells at the mRNA level and the trends
observed in the cell lines were also observed in
normal murine T cells. The authors of this study
implicated PKC h as having an important role in T
cell function. We have also described the expression
of PKC « , d and z in a T cell line and have
illustrated that individual isoforms are differentially
regulated following different methods of T cell acti-
w xvation 38 . PKC z has been implicated in IL-2
w xsignaling in a T cell line 39 suggesting a role for
Fig. 2. T cell proteins interacting with PKC and putative PKC functions. The evidence for these interactions is described in the text.
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this enzyme in cytokine signaling. We have illus-
trated that these isoforms are also expressed in hu-
w xman PBL’s 40 .
w xBaier et al. 12 were the first to describe PKC u
which they cloned following a novel screening strat-
egy for PKC isoforms selectively expressed in T
cellsrhematopoietic cells. This isoform has since
been shown to be involved in regulation of IL-2 gene
w xactivity 41 . The unique expression pattern and func-
tional properties of u suggested that it may play a
specialised role in T cell signalling pathways. It has
been reported that the HIV Nef protein, thought to be
involved in downregulation of CD4, associates with
PKC u and this association may result in impaired
PKC u mediated signal transduction in HIV infected
w xcells 42 . Recent studies on the function of this
isoform in T cells have described an association
between PKC u and a member of the 14.3.3 family
of proteins which may provide clues as to how this
w xisoform is regulated in vivo 43 .
The studies on calcium-independent PKC isoforms
have indicated that individual isoforms are differen-
tially regulated and have the potential to target differ-
ent effector molecules in T cells. Fig. 2 summarises
some of the isoform specific T cell interacting pro-
teins reported to date. The expression of one of the
newer members of the PKC family – m in murine
thymocytes and lymphocytes has recently been re-
w xported 44 . However, the functional role for this
 .isoform and PKC irl in T cells awaits clarifica-
tion.
2. PKC and T lymphocyte functions
2.1. PKC substrates in T cells
The conclusive identification of PKC substrates in
T cells has been limited by the lack of specific PKC
activators or inhibitors. Much of the data reported
identifying substrates for PKC has used phorbol es-
ters as T cell activators. Numerous other serine–
w xthreonine kinases have been described in T cells 28
and it is possible that some of the phosphorylations
described below could be attributed to kinases other
than PKC or alternatively may be mediated by ki-
nases that are activated by PKC. Thus phorbol ester
induced changes in phosphorylation status of these
putative PKC substrates may be an indirect effect of
PKC action. T cell molecules implicated as being
PKC substrates include surface molecules such as
CD3, CD4r8, IL-2 receptor and other signalling
molecules such as PLC and raf-1.
One of the first potential substrates for PKC to be
identified in T cells was the CD3 complex itself. CD3
g , d , and « subunits have been identified as targets
for serinerthreonine phosphorylation in T cells
w x45,46 . Phosphorylation is accompanied by a de-
crease in expression of the TCRrCD3 complex and
an increased rate of internalisation, decreasing cell
w xresponsiveness to stimulation via the TCRrCD3 46 .
Interestingly, PKC mediated phosphorylation has dif-
ferent effects on CD4 and CD8 coreceptors. PKC
mediated phosphorylation induces dissociation of
CD4 from the signalling molecule lck and internalisa-
tion; however, CD8 does not internalise or dissociate
w xfrom lck 47 . PKC has also been shown to phospho-
w xrylate lck 47 and other molecules involved in T cell
w x w xsignalling such as PLCg 48 and raf-1 28 thus
possibly implicating PKC in the regulation of both
 .it’s own activation lck, PLC g and the regulation of
 .other signalling pathways lck, raf-1 .
Studies examining the codistribution of PKC iso-
forms with subcellular lymphocyte components may
also identify potential substrates. PKC b has been
reported to codistribute with spectrin and ankyrin in
w xmurine peripheral blood lymphocytes 36 . PKC z
has been shown to colocalise with actin and regulate
w xits distribution in a T cell line 49 . These studies
suggest that components of the lymphocyte cyto-
skeleton important in T cell–APC interactions may
be target substrates for PKC isoforms. Many addi-
tional substrates identified in other cell types includ-
ing other components of the cytoskeleton and the
nucleus may also prove to be regulated by PKC in
lymphocytes.
In recent years a new area of PKC research has
evolved looking at the interaction of PKC with spe-
cific anchoring proteins known alternatively as recep-
 .tors for activated C kinase RACK , proteins that
 .interact with C-kinase PICK and the latest addition
w x
— the multi enzyme scaffolds or AKAP’s 50 . To
date no T cell specific PKC binding proteins that
function exclusively as PKC anchors have been found
although some authors have suggested that T cell
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proteins that can also modulate PKC activity may
w xserve as subcellular localising proteins 43 .
2.2. Effector molecules downstream of PKC
At least one downstream effector for PKC has
been identified in T cells. Raf- 1 is a serinerthreonine
kinase which is believed to be required for expression
of several T cell genes. Cross-linking of T cell anti-
gen receptors has been shown to lead to phosphoryla-
tion and activation of raf-1 in a PKC dependent
w xmanner 28 . Direct phosphorylation of raf-1 has
w xbeen reported by PKC a 51 . Ras has also been
shown to interact with raf-1 following stimulation of
T cells with phorbol esters or anti-T cell antigen
w xreceptor antibodies 52 . This kinase may therefore
act as a converging point for parallel signalling path-
ways originating at the T cell receptor–CD3 com-
plex.
The proto-oncogene pim-1 may represent another
downstream target for PKC in T cells. Pim-1, a
serine–threonine kinase whose mRNA is rapidly in-
duced following T cell activation, has been impli-
cated in intracellular signalling processes in T cells.
Pim-1 mRNA expression in anti-CD3 mediated T cell
activation has been shown to be associated with
activation of PKC, in particular PKC « and to be
w xindependent of raf-1 53 . Using constitutively active
mutated forms of PKC transfected into a T cell line
w xGenot et al. 54 have attempted to define the sig-
nalling pathways for individual PKC isoforms. The
data illustrated that ras, PKC a , and PKC « were
not positioned on a single linear signalling pathway.
Thus, in lymphocytes it would appear that different
PKC isoforms may be involved in separate signalling
pathways. Specific PKC isoforms may regulate addi-
tional signalling pathways originating at the T cell
surface membrane by signal cross talk.
Facilitatory and inhibitory effects of PKC on inosi-
tol lipid metabolism have been observed in lympho-
cytes. PKC mediated phosphorylation of PLC g has
been shown to decrease its activity and serves to
w xuncouple it from the TCR 55 . In other cell types
PKC has also been shown to regulate the activity of
DAG kinase. The concentration of DAG second mes-
sengers is regulated by this enzyme which decreases
DAG levels. Cotransfection studies have indicated
that DAG kinases are regulated by phosphorylations
w xmediated by specific PKC isoforms a and « 56 .
These isoforms could therefore be regulating the
activity of other DAG sensitive PKC isoforms. PKC
mediated activation of PLD has been reported in
various cell types. Specific PKC isoforms have been
implicated in PLD activation although the isoform
responsible in T lymphocytes has not yet been identi-
w x w xfied 10 . Mollinedo et al. 18 have illustrated that
PLD activation is associated with induction of AP-1
in T cells therefore it is possible that PKC mediated
activation of PLD serves to enhance gene transcrip-
tion, possibly during long term T cell responses. A
recent study has also suggested that PKC z has a
direct role in regulation of the functional activity of
w xPI-3 kinase in a T cell line 57 . Several other phos-
pholipasesrkinases have been implicated in the gen-
eration of activators for PKC in lymphocytes includ-
w xing PLA and PI-4 kinase 10 . It will be interesting2
to determine if these enzymes are also regulated by
PKC in lymphocytes and to further dissect the influ-
ence that PKC has on the control of its own activity.
Other systems on which PKC may exert an effect
include the adenylate cyclase system, tyrosine ki-
nases, phosphatases and calcium. A number of stud-
ies have suggested that cAMP production is altered
w xfollowing PKC activation 58 . It has been shown that
PKC increases adenylate cyclase activity both di-
rectly and indirectly in vitro. PKC phosphorylates
and inactivates G the inhibitory G protein whichi
w xrelieves inhibition of adenylate cyclase 59 . Differen-
tial activation of adenylate cyclase by direct phospho-
rylation mediated by specific PKC isoenzymes has
w xalso been illustrated in vitro 60 . A recent study has
provided evidence that type I protein kinase A
 .isozyme PKA-I is a downstream target for PKC in
w xT cells activated via the TCR–CD3 complex 61 . In
lymphocytes activation of adenylate cyclase and pro-
duction of cAMP generally leads to suppression of
w xlymphocyte activation 62 . PKC may therefore facili-
tate T cell activation by inhibition of adenylate cy-
clase.
Thus PKC can interact with several signalling
systems at a number of different levels including the
ras-raf-MAP kinase pathway and the calcium–
 .calmodulin pathway discussed in Section 2.4 and
can positively and negatively regulate the availability
of its own lipid cofactors. The cross talk between
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PKC and pathways important for regulation of cy-
tokine gene transcription JNK kinases, JAK-STAT
.pathway awaits clarification. As has been suggested
by some investigators it is also possible that different
w xPKC isoforms will ‘cross talk’ with each other 63 ,
perhaps acting as PKC-kinases upregulating the ki-
nase activity of a different isotype thus initiating a
PKC kinase cascade.
2.3. PKC and housekeeping functions in T cells
Prior to addressing the putative roles for PKC in
differentiated effector T cells we will firstly examine
the functions that PKC may regulate in all T cell
subpopulations with this section concentrating on the
role of PKC in regulation of lymphocyte adhesion
and cytoskeletal rearrangement. The next section ad-
dresses the evidence for a role for PKC in regulation
of cytokine gene expression focusing on expression
of IL-2.
The process of adhesion is important for the inter-
action of T cells with APC and target cells. LFA-1, a
member of the integrin family, is expressed on virtu-
ally all bone marrow derived cells including thymo-
cytes, T cells, B cells and monocytes. In T cells
LFA-1 is involved in both the interactions of T cells
with APC or target cells and in lymphocyte recircula-
tion. In a T lymphocyte cell line it has been shown
that engagement of the TCR–CD3 complex resulted
w xin a PKC mediated redistribution of LFA-1 64 .
Homotypic aggregation has also been shown to in-
w xvolve PKC as it can be induced by phorbol esters 65
in T cells. Changes in LFA-1 mediated adhesion are
also important for transmigration of activated lym-
phocytes and homing to target sites. Activation of
lymphocytes via the CD3 complex, the IL-2R or via
phorbol esters leads to an increase in LFA-1 medi-
w xated adhesion to endothelial cells 66 . This increased
adhesion is brought about by a change in affinity of
LFA-1 for its ligand rather than upregulation of its
expression. PKC mediated phosphorylation of LFA-
1b chain is thought to be involved in this change in
w xLFA-1 affinity 67 .
Induction of cytoskeletal rearrangement and
changes in lymphocyte motility have been reported to
occur following T cell modulation with PKC activa-
tors or inhibitors. Changes in lymphocyte motility are
important for the processes of naive lymphocyte re-
circulation and effector cell homing. Induction of
w xF-actin 68 and increased expression of spectrin ag-
w xgregates 69 have been reported to occur following T
cell stimulation with PKC activators. Redistribution
of lymphocyte cytoskeletal intermediate filament pro-
w x w xteins neurofilament 70 and vimentin 71 in re-
sponse to various methods of T cell stimulation have
been shown to be PKC dependent processes. Kelleher
w xet al. 71 illustrated that LFA-1 and CD44, important
molecules involved in lymphocyte migration, regu-
lated morphological changes in activated T cells in a
PKC dependent manner. The authors suggested that
these molecules transduce signals resulting in cyto-
skeletal rearrangements necessary for lymphocyte
trans-migration.
Studies examining the effects of PKC inhibitors on
lymphocyte motility have further implicated this en-
zyme in regulation of the lymphocyte cytoskeleton.
w xThorp et al. 72 examined the effects of a number of
PKC inhibitors on lymphocyte motility. The authors
illustrated that whereas most PKC inhibitors had the
capability to inhibit lymphocyte motility, a bisin-
dolylmaleimide PKC inhibitor stimulated lymphocyte
shape changes. Subsequent studies by Southern et al.
w x73 indicated that this inhibitor induced shape
changes in diverse populations of lymphocytes and T
cell lines and that Bryostatin mediated down-regu-
lation of PKC in PBLs also induced a motile pheno-
type. The data indicated that PKC mediated cyto-
skeletal phosphorylation maintains the lymphocyte in
a non-motile phenotype. The studies on cytoskeletal
rearrangements and those examining lymphocyte
motility suggest that different PKC isoforms may
exert positive and negative regulatory constraints on
the lymphocyte cytoskeleton. The bisindolyl-
maleimide inhibitors have been shown to be more
effective at inhibiting the conventional PKC isoforms
w xcompared to novel or atypical isotypes 74 . Thus
inhibition of conventional PKC isoforms or activation
of novelratypical isoforms may result in cytoskeletal
rearrangement and the acquisition of a motile pheno-
type in lymphocytes.
2.4. The role of PKC in cytokine gene transcription
The activation of cytokine gene transcription in T
cells involves the contribution of a distinct group of
enhancer elements. As is the case for the signalling
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pathways coupled to cytokine receptors the most
information is available about the IL-2 gene enhancer
region. In line with the observations that multiple
signals are required to activate IL-2 gene transcrip-
tion, the enhancer in the IL-2 promotor has at least
seven distinct binding sites for transcription factors
w x75 . The simultaneous presence of these factors is
required for maximal transcription. TCR activated
signalling pathways contribute to the activation of
several nuclear complexes that are known to regulate
cytokine gene expression by binding to the IL-2
enhancer region. These include NFk B, AP-1, NFAT
and octamer binding factors. These factors are impor-
tant for IL-2 gene transcription and several other
cytokine genes induced during T cell activation ap-
pear to use elements such as NFk B and AP-1 in a
similar manner, while other factors may be used in a
w xmore restricted manner 75 . This section concen-
trates on three transcription factors AP-1, NFAT and
NFk B. The evidence for the involvement of PKC in
their regulation is presented looking at studies that
have examined a transcription factor regulation in T
cells and other cells of the immune system. Fig. 1
outlines some of the reported interactions of specific
PKC isoforms with these transcription factors.
The activity of the AP-1 transcription factor is
induced by a wide range of stimuli in T cells and
other cells of the immune system. In T lymphocytes
AP-1 induction occurs after TCR cross-linking, IL-1
stimulation and can also be induced via phorbol
esters. The AP-1 gene transcription factor is com-
posed of a complex of the jun and fos proto-onco-
gene families whose activity is regulated by phospho-
rylation. As AP-1 activity could be induced in T
lymphocytes via phorbol esters, this suggested a role
for PKC in AP-1 regulation. It has been illustrated
that the phorbol ester induced activation of AP-1 may
be regulated by specific PKC isoforms. Constitutively
active PKCs a and « were shown to regulate the
activity of AP-1 in a T cell line whereas constitu-
w xtively active PKC z did not have this effect 54 .
PKC u has also been shown to stimulate transcrip-
tion from an AP1-element in a leukemic T cell line
w xand this has been reported to be ras dependent 76 .
It has been shown that the nuclear component of
NFAT is a complex of jun and fos gene products
w x77 . The functional NFAT complex consists of at
least two elements. The cytoplasmic phosphoprotein
NFAT that is dephosphorylated by thep
calciumrcalmodulin-dependent phosphatase cal-
cineurin and the nuclear component NFAT . Follow-n
ing T cell stimulation, activated calcineurin phospho-
rylates NFAT which then translocates to the nucleusp
where it combines with the newly synthesised nuclear
component NFAT . The synthesis of NFAT is de-n n
pendent on the activation of PKC, stimulated via the
w xT cell antigen receptor andror by phorbol esters 78 .
It is this nuclear subunit that contains the jun and fos
proteins. Thus the activity of NFAT, an important
regulator of cytokine gene expression, is regulated by
the synergistic action of calcium and PKC signalling
w xpathways. Genot et al. 54 illustrated that PKC «
and to a lesser extent PKC a were able to regulate
NFAT activity in a T cell line transfected with consti-
tutively active PKC isoforms.
The Rel family of transcription factors which in-
cludes NFk B, a ubiquitously expressed transcription
factor, appears to be required for the expression of
w xmany cytokines and their receptors 79 . Following
dissociation from its inhibitory protein Ik B, NFk B
must translocate to the nucleus to elicit its function
and a wide range of agents have been shown to
induce this translocation including bacterial and viral
pathogens, immune and inflammatory cytokines and
w xagents that damage cells 80 . PKC isoforms have
been implicated in NFk B activation in different cell
types. PKC « has been implicated in induction of
w xNFk B activity in T cells 54 and in rat 3Y1 fibrob-
w xlasts 81 . PKC z has also been implicated in NFk B
w xactivation in Xenopus lae˝is oocytes 82 . It is possi-
ble that certain PKC signalling pathways found in
other cells may also be conserved in T cells. For
example the ceramide-PKC z pathway described in
w xU937 cells 24 may also be used in T cell cytokine
signalling. In this regard it has been shown that other
cytokines such as IL-1 can induce sphingomyelin
turnover which results in the production of ceramide
w x83 and this may be an important conserved sig-
nalling pathway for cytokines in a variety of different
cell types.
We will now address what role PKC may play in
specific subpopulations of lymphocytes starting first
with the lymphocyte precursor — the thymocyte —
and then looking at the evidence that PKC plays an
important role in differentiated effector T helper and
cytotoxic cells.
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2.5. PKC in thymocytes
Some data has been described suggesting that con-
ventional isoform expression may be related to the
stage of thymocyte maturation. A study comparing
PKC a and b expression in double and single
positive human thymocytes indicated that these iso-
forms were differentially regulated during intra-
w xthymic development 84 . The PKC b isoform was
detected at the protein level in all subsets of thymo-
cytes isolated from human thymus, whereas the a
isoform was found only in single positive CD4q
w xthymocytes. However, Freire-Moar et al. 85 had
previously reported that in murine thymocytes no
correlation between PKC isoform expression and thy-
mocyte phenotype could be detected using PCR. The
differences in these two studies may reflect the species
differences or alternatively the different methods of
detection of PKC isotypes used. In the study by
w xFreire-Moar et al. 85 , distinct responses to activa-
tors were observed for calcium-independent isoforms
PKC « , z , and d . Whereas conventional PKC’s a
and b were down-regulated by a combination of
PMA and ionomycin, PKC « was resistant to PMA
mediated down-regulation in unfractionated thymo-
 .cytes measured at the mRNA level . In addition
PKC z was down-regulated by PMA and PKC d
expression was induced transiently only after activa-
tion of thymocytes with PMA or Concavin A. Thus it
would appear that PKC isoforms « , z , and d are
regulated in a distinct way in thymocytes compared
to other cell types and peripheral blood lymphocytes
in the mouse. This would suggest that these isoforms
may play a role in thymocyte development and pro-
gression of these cells to mature lymphocyte pheno-
types in the periphery. Changes in individual isoform
activation requirements or levels of expression may
regulate the physiological changes that occur during
the acquisition of a mature lymphocyte phenotype.
2.6. PKC in T helper cells
Fully differentiated effector T cells have been
subgrouped into CD4q T helper cells which interact
with and activate B cells and macrophages, and
q  .CD8 cytotoxic T cells CTL that kill target cells
expressing specific antigen. T helper cells can be
further subdivided into either Th1 or Th2 depending
on the patterns of cytokines they secrete. Th1 cells
produce IL-2, IFN-g and IL-12 whereas Th2 cells
w xproduce IL-4, IL-5, IL-6 and IL-10 86 . Differentia-
tion of T helper cells to Th1 or Th2 effectors is
driven by antigenic stimulation and biased towards
the expression of one subset by the presence of IL-12
or IL-4. IL-12 is secreted by monocytes, macrophages,
B cells and other accessory cells in response to
bacterial products or parasites and together with IFN-g
w xdrive the cell towards a Th1 cytokine profile 87 .
Th1 responses are thought to be important for immu-
nity to extracellular parasites and involve an inflam-
matory response and destruction of infected cells.
w xTh2 responses are driven by IL-4 88 and the Th2
response is thought to be important for immunity to
extracellular parasites, involving primarily an anti-
body response and activation of granulocytes.
The initial steps leading to activation of both T
helper and cytotoxic cells are thought to involve
similar signalling mechanisms as both types of cells
express TCR’s generated from the same T cell recep-
tor genes. Preliminary studies examining the differ-
ences in effector cell expression of PKC’s suggested
that conventional isoform expression may be related
w xto the lymphocyte subset. Gupta and Harris 32
examined PKC expression in T cell subsets using
flow cytometry and observed that CD4q and CD8q
lymphocytes express PKC a , b , and g with only
subtle differences in levels of expression. However,
differential translocation of these isoforms was re-
ported using this system following activation of lym-
w xphocyte subsets with PMA 32 . We have also re-
ported differential translocation of PKC isoforms in
PBLs following activation with PMA or anti-CD3
w xantibodies 40 . Donor specific variations in conven-
tional isoform expression have also been reported
w x w x84 . Tarantino et al. 84 illustrated that the PKC b
isoform could be detected at the protein level in all T
cell subtypes isolated from human peripheral blood,
whereas the a isoform was expressed consistently in
CD4q T cells and in a donor specific manner in
CD8q T cells.
With respect to T helper cell subsets little informa-
tion is available regarding the difference between
signalling pathways that are involved in the effector
functions of Th1 or Th2 cells. Kawakami and Parker
w x89 described evidence suggesting that Th1 and Th2
cells have different signalling pathways for induction
of contact dependent T cell help. The authors impli-
( )C. Keenan et al.rBiochimica et Biophysica Acta 1358 1997 113–126 123
cated PKC in Th1 signalling but not Th2 signalling.
The evidence for a PKC independent signalling path-
way in Th2 cells was largely obtained by PMA
mediated down-regulation. Given the cell type spe-
cific responses to PMA that have been reported and
the role of atypical PKC isoforms in T cell function it
is likely that the findings of this study will have to be
re-evaluated. The study does suggest however, that
 .different PKC’s phorbol resistant versus sensitive
may be involved in signalling in Th1 and Th2 cells.
Further studies have illustrated that PKC may play an
important role in Th1rTh2 differentiation at the level
w xof NFAT dependent transcription. Casolaro et al. 90
have shown that PKC activation leads to develop-
ment of a Th1 helper cell subset via activation of
IL-2 gene transcription and repression of IL-4 gene
transcription. This study does not, however, address
the specific isoforms involved in the regulation of
IL-2rIL-4 gene transcription.
In addition to the regulation of cytokine expression
the action of PKC may also have an influence on
other aspects of helper T cell function. As mentioned
in previous sections PKC is involved in the signalling
pathways initiated by cross-linking of the TCR–CD3
complex. In addition the PKC mediated changes in
adhesion molecule expressionravidity may be impor-
tant for helper T cell interaction with both APC and
target B cell. PKC mediated cytoskeletal rearrange-
ments in T helper cells may also be important for
lymphocyte transmigration and directional release of
cytokines in the vicinity of B cell contact.
2.7. PKC and cytotoxic T cells
Maturation of cytotoxic T cells requires two stim-
uli — the interaction with antigen presented in the
context of MHC class I and stimulation by CD4q T
w xcell derived cytokines 91 . The signalling mecha-
nisms initiated by TCR–CD3 cross-linking result in
the expression of cytokine receptors and the acquisi-
tion of responsiveness to cytokines secreted by the
helper T cell including IL-2, IL-4, IFN g and IL-6
and ultimately the ability of these cells to lyse target
cells. Mature CTL’s develop specific membrane
bound cytoplasmic granules in addition to the capa-
bility to transcribe and secrete cytokines such as
IFNg and other proteins important in target cell lysis.
These cells are the main effector arm of the immune
system involved in elimination of virally infected
cells. CTL’s both specifically recognise and lyse their
target cells. Target cell lysis is mediated by two
mechanisms involving a perforin–granzyme based
w x w xmechanism 92 and an apoptotic mechanism 93 .
The involvement of PKC in CTL effector func-
tions may occur at a number of different levels. As
mentioned in previous sections PKC can regulate
lymphocyte–target cell adhesion by increasing the
affinity of surface molecules like LFA-1 for their
coreceptors on target cells. PKC regulation of lym-
phocyte motility is also important for the ability of
CD8q cells to ‘see’ antigen and to home to target
sites. In addition PKC is involved in the signalling
pathways initiated by cross-linking of the TCR–CD3
complex. Evidence is now accumulating that PKC
may also be involved in both perforin based and Fas
based CTL killing of target cells. The information to
date on the role of PKC in CTL target cell killing is
examined in the next section.
w xTing et al. 94 have provided evidence that PKC
may be involved in perforin mediated killing by
illustrating that following anti-CD3 stimulation the
generation of a killer T cell response was PKC
dependent. These authors examined the activity of
lytic enzymes and the expression of perforin mRNA
as markers of CTL function and illustrated that PKC
inhibitors could block these responses. Thus PKC
may be involved in the regulation of lytic enzymes
and the expression of components of the cytoplasmic
CTL granules. PKC activators can also induce
changes in the lymphocyte cytoskeleton which may
be important for focusing and exocytosis of cytoplas-
mic granules during perforin based killing.
The second method of CTL killing involves initia-
tion of apoptosis in target cells by the interactions of
Fas and FasL and has only recently been charac-
w x terised 93 . Fas, a member of the TNFrNGF nerve
.growth factor receptor family, is highly expressed on
w xactivated mature lymphocytes 95 . The expression of
Fas is upregulated by IFN g in various cell lines. The
ligand for Fas termed FasL has significant homology
to members of the TNF family and its expression is
more restricted than Fas. FasL expression on the
cytotoxic cell occurs following CTL recognition of
target cells. Engagement of FasL on CTL and Fas on
target cells then leads to activation of an intrinsic
w xsuicide program in the target cell 93 . It has been
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suggested that PKC also plays an important role in
the Fas–FasL based target cell killing as the expres-
sion of FasL in T cells has been shown to be rapidly
induced by activation with PMA and ionomycin or
w xby T cell receptor engagement 96,97 .
In addition to having an effect on cytokine gene
transcription via activation of transcription factors, it
has been illustrated that PKC can regulate IFN g
expression by post-translational modification of IFN
w xg mRNA in a cytotoxic T cell clone 98 . Thus PKC
may be involved in regulation of CTL function at a
number of different levels. Future studies are required
to determine which PKC isoforms are involved in
regulation of FasL expression and perforin based
lysis and what upstream signalling pathways regulate
these isoforms in CTL’s.
2.8. PKC and memory T cells
Few studies have addressed the differences in sig-
 q.nalling between naive CD45RA and memory
 q. w xCD45RO T helper or CTL’s. Robinson et al. 99
reported that CD45ROq cells had higher basal levels
of DAG and higher CD3 induced elevation of intra-
cellular calcium and PKC activity than CD45RAq
w xcells. Corrigan et al. 100 illustrated that there was
no difference in the PKC isoform profile of
CD45RAq and CD45ROq cells, however CD45RAq
cells were shown to have higher levels of PKCs a ,
b , and d than CD45ROq cells. The differences
observed between the two studies possibly reflect the
different techniques utilised kinase assay versus flow
.cytometryrWestern blotting . It would appear that
the overall PKC isoform profile is not different be-
tween memory and naive cells, however the levels of
PKC isoforms expressed in the subsets may be differ-
ent. Little is known regarding the signalling pathways
involved in the progression of activated T
helperrCTL to memory cells. It is possible that cross
talk between the different CD45 isoforms and lym-
phocyte signalling pathways such as those involving
PKC are involved in the process of lymphocyte mem-
ory cell differentiation.
3. Concluding remarks
The experimental tools used to elucidate the role
of PKC in lymphocytes have evolved since the initial
w xreports describing its presence in T cells 101,102 .
The key areas to address in the future relate to the
isoform specific functions in T cells and thus the
relationship between subcellular localisation, activa-
tion requirements and function of individual isotypes.
Several studies have taken steps towards elucidating
isoform specific functions. The major challenge fac-
ing researchers in this area is to generate the tools
necessary for the dissection of individual functions
for PKC isoenzymes.
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